CorMedix (CRMD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.29
- Estimate
- $0.24
- Surprise
- +21.9%
- Revenue (period 2026-06-30)
- $101.9M
- Score today
- 6.9/10
Revenue source: xbrl.
How the report landed
CorMedix (CRMD) beat the $0.24 estimate with diluted EPS of $0.29 — a large 21.9% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CRMD Buy (Wait) at 6.9/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +21.9% surprise compares with a +17.3% four-quarter average. Next scheduled report: 2026-11-16.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=9.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Customer: top three customers (79.0%)
- Earnings expected to decline ~84% (cyclical peak)
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.58
- Entry target
- $8.47
- Price target
- $13.40
- Stop
- $7.98
- Upside to target
- +76.8%
- Reward-to-risk
- 11.4:1
Forward estimates sit below the trailing run-rate (22.2× forward vs 3.6× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
CRMD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $604.8M
- P/E (fwd)
- 22.2
- P/E (ttm)
- 3.6
- 52-week range
- $6.13–$13.02
- Off 52-week high
- 41.8%
- RSI (14)
- 31
- Volume vs avg
- 0.70×
- Score today
- 6.9/10